To evaluate the efficacy of incomplete treatment protocols of cisplatin in concurrent chemoradiation for locally advanced cervical carcinoma. This retrospective study was performed in 165 consecutively treated patients with locally advanced cervical cancer who received a weekly cisplatin regimen. The number of weekly cisplatin cycles of each patient was recorded and used to discriminate between patients. Local control, disease free survival, distant metastasis-free survival, and toxicities were calculated using the software package SPSS version 15.0. Ninety-two patients (55%) completed the planned protocol of six cycles of weekly cisplatin. With the median follow-up time of 38.2 months, the 3-year local control rate differed significantly in the two patient groups (95.4% of 6 cycles versus 84.8% of < 6 cycles; p = 0.028). No statistical significance was observed for disease-free survival (74.6% versus 74.5%; p = 0.22) and distant metastasis-free survival (76.5% vs. 75.7%; p = 0.88). In conclusion, the plan completion of concurrent cisplatin with radiotherapy was responsible for better local control. However, differences in disease-free survival and distant metastasis-free survival were not statistical significant.
INTRODUCTION
Cervical cancer is the most common cancer in Thai females. The incidence of cervical cancer in Chiang Mai was 29.7 per 100,000. 1) In advanced disease (stage IIB-IVA), concurrent chemoradiation is standard treatment and platinum-based chemotherapy protocols are preferable. [2] [3] [4] [5] Weekly cisplatin regimen is one of the most common formulas. During irradiation, weekly cisplatin -used and six cycles of cisplatin during irradiation-is standard. However, due to toxicities of chemoradiation, some patients cannot tolerate all courses of regimen. 6) Thus, dose-intensity of chemotherapy questions the effect on the end results. To clarify this question we performed a retrospective study to identify the effect on disease control of cervical carcinoma in patients receiving less than six cycles of treatment comparing with patients who received the complete schedule of chemotherapy.
MATERIALS AND METHODS

Patients
Retrospective data collection was performed in 165 consecutively treated patients with locally advanced cervical cancer, who received during the radiotherapeutic treatment a concurrent weekly cisplatin regimen. Patients included in this study showed up with International Federation of Gynecology and Obstetrics (FIGO) stages IIB-IVA, good performance status (ECOG 0-1), no uncontrolled concomitant disease, no connective tissue disease, and no prior irradiation. Patients who received complete 6 cycles of cisplatin were grouped as complete plan group (group I) and patients who received chemotherapy less than 6 cycles were grouped as incomplete plan group (group II).
Radiation therapy
Radiotherapeutic schedule was composed of external beam radiation therapy (EBRT) in conventional fractionation (2 Gy per fraction, 5 fractions per week) using a 6 MV photon beam from a linear accelerator. A total dose of 50 Gy was administered to the whole pelvis with 4 cm central shielding after 40 Gy. Parametrial boost was added to the total dose of 56 Gy. Intracavitary brachytherapy (ICBT) at the dose of 6 Gy in 4 fractions or 7.2 Gy in 3 fractions to 
Chemotherapy
Chemotherapy consisted of cisplatin administered weekly at a dose of 40 mg/m 2 for all patients. A maximum dose of cisplatin up to 70 mg was administered to total comprising all 6 cycles. Pre-and post-chemotherapy fluid hydration was given and ondansetron (8-16 mg) was routinely administered on the day of chemotherapy as an anti-emetic treatment. Patients were seen weekly by a physician for a physical examination and blood tests of complete blood count (CBC), blood urea nitrogen (BUN) and serum creatinine (Cr). A 50% dose reduction was prescribed in patients who had creatinine clearance (CCr) less than 50 ml/min but not less than 40 ml/min. If the Ccr was less than 40 ml/min but not less than 30 ml/min, chemotherapy has been postponed for one week until recovery occurred. Chemotherapy was stopped when the creatinine clearance was less than 30 ml/ min and interrupted if patients had grade 3 or greater gastrointestinal toxicity, the total white blood cell count ≤ 3,000/mm 3 , or platelets ≤ 100,000/mm 3 . Granulocyte colony-stimulating factors were used when absolute neutrophil count fell ≤ 500/mm 3 or total white blood cell count fell ≤ 1,000/mm 3 .
Toxicity
During treatment, toxicities were assessed weekly and graded according to the National Cancer Institute Common Terminology Criteria of Adverse Events (version 3.0). 7) Toxicities were evaluated and stratified by the defined patient groups.
Statistical analysis
Dose-intensity (number of cycle) of weekly cisplatin of each individual patient was recorded and patients were analyzed according the number of completed chemotherapy cycles. Survival data, disease control, and toxicities were calculated using the software package SPSS version 15.0. The Kaplan-Meier approach and the log-rank test were used to compare survival profiles between defined patient groups.
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RESULTS
From January 2004 to December 2006, 165 patients were included.
Ninety-two patients (55.8%) completed the six cycles of weekly cisplatin while 73 patients (44.2%) received less than 6 cycles. The most common causes of incomplete plan of chemotherapy were neutropenia (31.5%), nephrotoxicity (27.4%), anemia plus neutropenia (8.2%) and others (32.9%). Detailed information on patients who received chemotherapy from 1 to 6 cycles is shown in Table 1 . Table 2 contains stratification of patients characteristics by the two defined treatment groups (group I and group II).
With the median follow-up time of 38.2 months (range 2.1-72.9 months), local control, disease free survival and distant metastasis free survival rates were 95.4%, 74.6%, 76.5% in group I (complete 6 cycles), and 84.8%, 74.5%, 75.7% in group II (< 6 cycles), respectively. Only local control showed in univariate analyses statistical significant differences (p = 0.028). All data details of both groups were shown in Table 3 and Fig. 1 .
Stratified by stage, local control, disease-free survival and distant metastasis-free survival rates were in stage IIB patients 97%, 76.8%, 79.3% for group I (complete 6 cycles), and 94.1%, 71.8%, 74.8% for group II (< 6 cycles), respectively. In stage IIIB patients, local control, disease-free survival and distant metastasis-free survival rates were 90.5%, 66.3%, 66.3% for group I (complete 6 cycles), and 65%, 42.8%, 66.4% for group II (< 6 cycles), respectively. All outcomes are detailed in Table 4 and Fig. 2-3 .
Toxicity
Grade 3 to 4 anemia, neutropenia and nephrotoxicity were found in 11, 25 and 3 patients, respectively. In patient group I, 3 and 8 patients showed grade 3-4 anemia and neutropenia, respectively. No patients developed grade 3-4 nephrotoxicity. When considered in patient group II, grade 3-4 anemia and neutropenia was found in 8 and 17 patients, respectively. Three patients developed grade 3-4 nephrotoxicity. There were statistical significances between the two groups on aspects of leucopenia and nephrotoxicity. No difference of late toxicity was found. All toxicity profiles are shown in Tables 5, and 6 .
DISCUSSION
The standard treatment of locally advanced cervical cancer is concurrent chemoradiation. Five randomized trials were published to support the use of concurrent chemoradiation in radical and postoperative settings with the relative risk of death in comparison groups of 0.50-0.72. based regimen is accepted to be the standard due to good effectiveness and acceptable toxicity when compared with alternative protocols. 10) However, cisplatin is associated with acute toxicities. A series of literature reports revealed reduced compliance using concurrent chemoradiation with cisplatin. The majority of studies showed that 74-93% of patients received more than 3 cycles of cisplatin. 4, [11] [12] [13] In the present study, 55% of patients completed 6 cycles of chemotherapy and 87.3% of all analyzed patients received more than 3 cycles of cisplatin.
Nowadays, the optimal schedule of weekly cisplatin is still controversial. Sirak et al. showed the results of 40 patients treated with concurrent chemoradiation. In patients with IIB stage, two-year disease-free survival (DFS) dependent on the number of cisplatin doses was 77% (> or = 3 doses) versus 56% (< 3 doses). 14) Our study could also demonstrate a decreased effectiveness of weekly cisplatin when given less than six cycles of cisplatin. However, statistical significance was reached only in 3-year local control (95.4% vs. 84.8%; p = 0.028). In terms of disease-free survival (74.6% vs. 74.5%; p = 0.22) and distant metastasis-free survival (76.5% vs. 75.7%; p = 0.88) statistical significant differences were not observed. When considering stage IIB only, statistical significance for 3-years local control, disease-free survival and metastasisfree survival was not found in patients with less than six cycles of cisplatin: 3 year local control (97% vs. 94.1%; p = 0.52), disease-free survival (76.8% vs. 71.8%; p = 0.92) and distant metastasis-free survival (79.3% vs. 74.8%; p = 0.71). This was also true for stage IIIB, statistical not significant differences were found in 3 year local control (90.5% vs. 65.0%; p = 0.19), disease-free survival (66.3% vs. 42.8%; p = 0.31) and distant metastasis-free survival (66.3% vs. 66.4%; p = 0.73).
In conclusion, the plan completion of concurrent cisplatin with radiotherapy was critical and associated with better local control in the entire patient group. Stratification by FIGO stage led to loss of statistical power, thus, statistical significance was not observed when considering IIB and IIIB stages separately.
Obviously, patients in the incomplete treatment group II had significantly more neutropenia (p = 0.01) and nephrotoxicity (p = 0.01) in comparison with the complete plan group I, because this was in general the cause of impaired compliance this study (31.5% of neutropenia and 27.4% of nephrotoxicity). These findings are in concordance with the literature as well.
The authors recognize the limitations of the present study using a retrospective analysis design and probably an insufficient sample size for subgroup calculations according FIGO stage. However, the present study might be of significant importance in order to point out the need of treatment plan completion of concurrent chemoradiation using cisplatin, which is considered standard treatment in advanced cervical cancer. These findings are particularly noticeable because randomized trials for ethical reasons cannot be carried out to address specifically the impact of treatment compliance.
